Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18956248 | 0.78 | NR1H2 (0.36) | NR1H2PARP1ALDH1A1PDPK1PIM1 | |
| SCHEMBL6201737 | 0.77 | NR1H2 (0.42) | NR1H2ALDH1A1BRD4 | |
| SCHEMBL5989848 | 0.70 | KDM4E (0.37) | ALDH1A1KDM4E | |
| SCHEMBL13189585 | 0.70 | NR1H2 (0.45) | NR1H2PARP1ALDH1A1BRD4HTT | |
| SCHEMBL2445832 | 0.70 | NR1H2 (0.39) | NR1H2PARP1ALDH1A1BRD4HTT | |
| SCHEMBL11971301 | 0.69 | ALDH1A1 (0.38) | NR1H2ALDH1A1BRD4 | |
| SCHEMBL24458506 | 0.68 | NR1H2 (0.43) | NR1H2PARP1ALDH1A1BRD4PDPK1 | |
| SCHEMBL4050177 | 0.68 | NR1H2 (0.46) | NR1H2PARP1ALDH1A1BRD4PDPK1 | |
| SCHEMBL5988830 | 0.68 | XDH (0.35) | KDM4E | |
| SCHEMBL24393300 | 0.67 | MEN1 (0.38) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497401-B2 | Substituted tetrazoles as TRPA1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-12-16 | — | — | US | disclosed |
| US-20240101561-A1 | NOVEL TETRAZOLES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2024-03-28 | — | — | US | disclosed |
| EP-4045053-B1 | NOVEL TETRAZOLES | BOEHRINGER INGELHEIM INT (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-3741758-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-11-25 | — | — | EP | disclosed |
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
| WO-2017064068-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2017-04-20 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
| WO-2008057402-A2 | N-ARYL-ISOXAZOLOPYRIMIDIN-4-AMINES AND RELATED COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20060264624-A1 | Methods for synthesizing imidazotriazinones | LEXICON GENETICS INCORPORATED | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | NR1H2 414/4885PARP1 300/4885ALDH1A1 3333/4885 |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | NR1H2 3227/4885PARP1 1557/4885ALDH1A1 3179/4885 |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | NR1H2 521/4885PARP1 3336/4885ALDH1A1 665/4885 |
| US-20240101561-A1 | NOVEL TETRAZOLES | TRPA1, TRPV1, TRPV5 | NR1H2 1582/4885PARP1 3747/4885ALDH1A1 1405/4885 |
| US-12497401-B2 | Substituted tetrazoles as TRPA1 inhibitors | TRPA1, TRPV1, TRPV2 | NR1H2 1363/4885PARP1 3093/4885ALDH1A1 1673/4885 |
| US-20060264624-A1 | Methods for synthesizing imidazotriazinones | PDE3A, PDE2A, PDE3B | NR1H2 3236/4885PARP1 1657/4885ALDH1A1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.